|
(Health-NewsWire.Net, August 05, 2015 ) Ovarian are the organ in the female reproductive system. They are of the shape of almond. There are around thirty types of Ovarian cancer. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.
Inquire more about this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=395196 . (This is a premium report price at US$2000 for a single user PDF license)
The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Complete Report is available at http://www.rnrmarketresearch.com/epithelial-ovarian-cancer-pipeline-review-h1-2015-market-report.html .
Scope of the Report:
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
• A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
Inquire for discount of this report at http://www.rnrmarketresearch.com/contacts/discount?rname=395196 . (This is a premium report price at US$2000 for a single user PDF license)
Reasons to buy:
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
Table of Contents:
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Epithelial Ovarian Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Epithelial Ovarian Cancer - Overview 11
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 12
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 13
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 18
Epithelial Ovarian Cancer - Pipeline Products Glance 19
More reports on cancer therapeutics are available at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
